Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Randomized Double-Blind Placebo-controlled Single and Multiple Ascending Dose Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis or Atopic Dermatitis

Trial Profile

A Phase 1 Randomized Double-Blind Placebo-controlled Single and Multiple Ascending Dose Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis or Atopic Dermatitis

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EDP-1815 (Primary)
  • Indications Atopic dermatitis; Psoriasis
  • Focus Adverse reactions; First in man
  • Sponsors Evelo Biosciences
  • Most Recent Events

    • 05 Nov 2019 According to an Evelo Biosciences Media Release, data will be presented at a future scientific conference or medical meeting.
    • 05 Nov 2019 Interim results (N=18) presented in an Evelo Biosciences Media Release.
    • 05 Nov 2019 According to an Evelo Biosciences media release, the company will host a conference call and webcast to review the new clinical data for EDP1815.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top